Tempus AI(TEM)

Background The prognostic value of FGFR3 pathway activation in patients with muscle- invasive bladder cancer (MIBC) treated with neoadjuvant chemotherapy (NAC) has not been established. Activation of FGFR3 signaling drives a subset of urothelial bladder cancers and classically results from pathogenic gene mutations (mut) or fusions (fus). Additionally, an RNA signature (FGFR-PRS) representing activation of … Continued The post Impact of FGFR3 Pathway Activation in Patients with Muscle-Invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy appeared first on Tempus .

Background HLA genotyping, specifically HLA-A*02:01 is an actionable marker in uveal melanoma for Tebentafusp, a bispecific gp100 peptide-HLA-directed CD3 T cell engager, with ongoing clinical trials investigating its use in HLA-A*02:01 positive cutaneous and mucosal melanoma. However, prior work has shown a discrepancy in this marker between blood and somatic tumor testing (Seedor R et … Continued The post A New HLA Genotyping Algorithm Shows Extremely High Accuracy and Concordance Between Tumor and Normal Samples appeared first on Tempus .

Background Categorizing gene fusions as drivers or passengers is a data-intensive challenge requiring manual interventions in all but the most well-established biomarkers. The large numbers of structural variants identified from genomic assays require a combination of tools to prioritize clinically relevant mutations in a timely manner. Recent advances in artificial intelligence (AI) and AI-agents have … Continued The post Retrospective Evaluation of an AI-Based Fusion Prioritization Agent for Oncogenicity Assessment in Clinical Sequencing appeared first on Tempus .

Background Patients with breast cancer frequently experience anxiety and depression, yet systemic delays in psychiatric care often leave oncologists to manage these conditions. The recent adoption of DPYD genotyping into NCCN guidelines for fluoropyrimidine safety marks a shift toward routine pharmacogenomic (PGx) integrations in oncology. This creates an opportunity to expand PGx to supportive care, … Continued The post Provider Insights and Utilization of Psychiatric Pharmacogenomics for Patients With Comorbid Breast Cancer and Emotional Distress appeared first on Tempus .

Background Neuroendocrine carcinoma (NEC) of the bladder is a rare and aggressive cancer with limited treatment options. Recent studies reported molecular subtypes resembling small cell lung cancer (SCLC), specifically those associated with transcription factors (TFs) ASCL1, NEUROD1, and POU2F3. A subset of bladder NEC remains unclassified. ATOH1 was recently identified as a TF associated with … Continued The post Molecular Classification of Neuroendocrine Carcinoma of the Bladder appeared first on Tempus .

Background ESR1 mutations (ESR1m) are known drivers of resistance to aromatase inhibitors. While ESR1m has been linked to worse survival outcomes, clonal complexity over time has not been well-evaluated in a real-world context. Here we characterized longitudinal dynamics of ESR1m, including rare point mutation emergence and polyclonality in hormone receptor- positive/HER2-negative metastatic breast cancer (HR+/HER2- … Continued The post ESR1 Mutation Longitudinal Dynamics in RWD Cohort of HR+/HER2- Metastatic Breast Cancer Patients Treated With Standard of Care Hormonal Therapy appeared first on Tempus .

Background Immune checkpoint inhibitors (ICI) have altered the oncology treatment landscape with improved outcomes. Despite approved predictive biomarkers for ICI such as TMB, refining selection can identify more patients (pts) who may benefit, as most TMB-H pts still fail to achieve response, a critical translational gap. Here we introduce IPS, a validated multimodal DNA-/RNA-based molecular … Continued The post Multimodal Immune Profile Score (IPS) Signature as a Predictive Response Biomarker to Immune Checkpoint Inhibitors in Tumor Mutational Burden-High (TMB-H) Advanced Pancancer Cohorts appeared first on Tempus .

Background Identifying structural rearrangements and gene fusions is critical to providing high quality, precision-driven clinical care for many types of pediatric cancers. RNA next-generation sequencing (NGS) provides a functional readout of the genome that enables superior detection of chimeric transcripts and novel driver fusions, particularly when genomic breakpoints reside in complex intronic regions. This study … Continued The post Concurrent RNA- and DNA-NGS Testing for the Detection of Clinically-Relevant Fusions In Pediatric Solid-Tumor Patients appeared first on Tempus .

Background BRAF mutations are present in approximately 40%–60% of patients with DTC. Lenvatinib is the NCCN Category 1 preferred first-line (1L) systemic therapy for progressive radioiodine-refractory (RAI-R) DTC—including BRAF-mutated disease. For patients with BRAF V600E–positive, RAI-R DTC, BRAF-targeted therapy is recommended for those unsuitable for lenvatinib or as a 2L agent for patients after disease … Continued The post First-Line Lenvatinib Versus Dabrafenib Plus Trametinib (D+T) in BRAF-Mutated Differentiated Thyroid Cancer (DTC): Insights From Real-World Data appeared first on Tempus .

Background TMB-high pMMR mCRC patients (pts) do not seem to derive benefit from immune checkpoint inhibitors (ICIs). In the CO.26 trial, pMMR/MSS mCRC pts with high baseline pTMB had better outcome with ICIs than those with low pTMB. Moreover, in the AtezoTRIBE study, tissue TMB was identified as a promising biomarker able to identify a … Continued The post Plasma-TMB (pTMB) and Circulating Tumor Fraction (ctF) Dynamics As Biomarkers of Benefit From the Addition of Atezolizumab to First-Line FOLFOXIRI/Bevacizumab in Metastatic Colorectal Cancer (mCRC): A Translational Analysis of the AtezoTRIBE Study appeared first on Tempus .

Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and CAP-accredited prognostic test will be fully integrated into the Tempus platform, providing urologists and oncologists with a digital pathology solution that helps inform personalization of therapy intensity in patients with … Continued The post Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use appeared first on Tempus .